GlyProVac - About the company
GlyProVac is a seed company based in Odense (Denmark), founded in 2015 by Anders Boysen and Ann Zahle Andersen. It operates as a Developer of glycoprotein-based vaccine against bacterial infections. GlyProVac has raised $354K in funding, with a current valuation of $*****. The company has 202 active competitors, including 60 funded and 45 that have exited. Its top competitors include companies like ImmunityBio, Evofem and Insmed.
Company Details
Developer of glycoprotein-based vaccines against bacterial infections. Its technology is based on BEMAP, a sample enrichment mass spectrometry method which allows the identification of any type of O-linked protein glycosylation which is used for E.coli, shigella, and others. Based on this technology, it has identified that glycoproteins are the reservoir of targets for antimicrobial intervention.
Key Metrics
Founded Year
2015
Location
Odense, Denmark
Stage
Seed
Total Funding
$354K in 2 rounds
Latest Funding Round
Post Money Valuation
$***** as on Sep 30, 2020
Investors
Ranked
75th among 202 active competitors
Employee Count
8 as on May 31, 2026
Similar Companies
Legal entities associated with GlyProVac
GlyProVac is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
GlyProVac ApS CIN: 39724758 , Denmark, Active | - | 6 (As on Mar 31, 2024) |
Sign up to download GlyProVac's company profile
GlyProVac's funding and investors
GlyProVac has raised a total funding of $354K over 2 rounds. Its first funding round was on 2015. GlyProVac has 3 institutional investors.
Here is the list of recent funding rounds of GlyProVac:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Sep 30, 2020 | 8367887 | Seed | 6617461 | 6043869 | 2011043 | 4242933 |
2015 | 4179 | Grant (prize money) | 1830 | 1753 | 4595 |
Access funding benchmarks and valuations. Sign up today!View details of GlyProVac's funding rounds and investors
GlyProVac's founders and board of directors
Founder? Claim ProfileThe founders of GlyProVac are Anders Boysen and Ann Zahle Andersen.
Here are the details of GlyProVac's key team members:
- Anders Boysen: Co-Founder & CEO of GlyProVac. They serve on the board of 1 company.
- Ann Zahle Andersen: Co-Founder of GlyProVac. They serve on the board of 1 company.
GlyProVac's Board of Directors
GlyProVac's board has 3 active members. Anders Boysen, Ann Zahle Andersen and Kirsten Winther are part of team.Here is the list of GlyProVac's board of directors:
Name | Type | Representing | Status | Duration |
|---|---|---|---|---|
Team | - | Current | 7y 10m | |
Team | - | Current | 7y 10m | |
hanf{uc | Team | - | Current | 4y 2m |
View details of GlyProVac's Founder profiles and Board Members
GlyProVac's employee count trend
GlyProVac has 8 employees as of May 26. Here is GlyProVac's employee count trend over the years:
Uncover GlyProVac's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
GlyProVac's Competitors and alternates
Top competitors of GlyProVac include ImmunityBio, Evofem and Insmed. Here is the list of Top 10 competitors of GlyProVac, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  ImmunityBio 2014, El Segundo (United States), Public | Developer of peptide-based vaccines for immunotherapy | $169M | 67/100 | |
2nd | Evofem 2009, San Diego (United States), Public | Developer of sexual and reproductive health therapeutics | $100M | 66/100 | |
3rd | Insmed 1999, Bridgewater (United States), Public | Developer of small molecule inhibitors for rare lung diseases | - | 66/100 | |
4th | Developer of vaccines against constantly mutating pathogens | $42.2M | 64/100 | ||
5th |  Brii Biosciences 2018, San Francisco (United States), Public | Developer of biologics to treat hepatitis B infection | $415M | 63/100 | |
6th | SNIPR Biome 2011, Copenhagen (Denmark), Series B | Developer of CRISPR-based microbial gene therapy to target pathogenic bacteria precisely | $139M | 63/100 | |
7th | SpyBiotech 2017, Oxford (United Kingdom), Series A | Developer of vaccines for bacterial infections and cancer by using proprietary protein superglue technology | $39M | 61/100 | |
8th | CStone Pharma 2016, Shanghai (China), Public | Developing and licensing novel drugs for diseases including cancer and autoimmune diseases | $410M | 59/100 | |
9th | Basilea 1999, Basel (Switzerland), Public | Developer of antibiotics, antifungals, and oncology drugs for treating multiple diseases | - | 59/100 | |
10th | Centauri Therapeutics 2014, Kent (United Kingdom), Series A | Developer of immunotherapeutics to treat infectious diseases | $73M | 58/100 | |
75th | Developer of glycoprotein-based vaccine against bacterial infections | $354K | 36/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on GlyProVac's competitors? Click here to see the top ones
GlyProVac's Investments and acquisitions
GlyProVac has made no investments or acquisitions yet.
News related to GlyProVac
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about GlyProVac
Explore our recently published companies
- Pcrpolyweld - Australia based, Unfunded company
- Pendergrastandassociate - Unfunded company
- Manwithvannorthockendon - Unfunded company
- Ai-First Team - Unfunded company
- Theaiparagonconsulting - Unfunded company
- Thorncapstead Shop - Unfunded company
